FigureS4 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS4 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

<p>FigureS4</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Jonathan Chou (14957015) (author)
Άλλοι συγγραφείς:	Emily A. Egusa (14962343) (author), Sinan Wang (14962346) (author), Michelle L. Badura (14962349) (author), Fei Lee (14962352) (author), Anil P. Bidkar (14962355) (author), Jun Zhu (14962358) (author), Tanushree Shenoy (14957003) (author), Kai Trepka (14962361) (author), Troy M. Robinson (14962364) (author), Veronica Steri (14962367) (author), Jiaoti Huang (14962370) (author), Yuzhuo Wang (14962373) (author), Eric J. Small (14962376) (author), Emily Chan (14962379) (author), Bradley A. Stohr (14962382) (author), Alan Ashworth (14957030) (author), Brant Delafontaine (14962385) (author), Sylvie Rottey (14962388) (author), Keegan S. Cooke (14962391) (author), Nooshin Hashemi Sadraei (14962394) (author), Brian Yu (14962397) (author), Mark Salvati (14962400) (author), Julie M. Bailis (14962403) (author), Felix Y. Feng (14845891) (author), Robert R. Flavell (9563200) (author), Rahul Aggarwal (14960826) (author)
Έκδοση:	2025
Θέματα:	Cancer Therapeutic Research and Development Immuno-oncology Methods and Technology Drug Targets Cell surface receptor drug targets Genitourinary Cancers Prostate cancer Imaging Positron emission tomography (PET) Immunotherapy Preclinical Models Xenograft models
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια

FigureS1 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

FigureS10 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

FigureS2 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

FigureS3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

FigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

FigureS6 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

FigureS7 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

FigureS8 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

FigureS9 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

Supplementary MovieS 1a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

Supplementary MovieS1b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

Supplementary MovieS1c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

Supplementary MovieS1d from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

Supplementary MovieS2a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

Supplementary MovieS2c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
ανά: Jonathan Chou (14957015)
Έκδοση: (2025)

Supplementary Video S1 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
ανά: Xiaojiang Duan (15439264)
Έκδοση: (2025)

Supplementary Video S2A from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
ανά: Xiaojiang Duan (15439264)
Έκδοση: (2025)

Supplementary Video S2B from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
ανά: Xiaojiang Duan (15439264)
Έκδοση: (2025)

Supplementary Video S2C from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
ανά: Xiaojiang Duan (15439264)
Έκδοση: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
ανά: Yuncheng Bei (16546095)
Έκδοση: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
ανά: Yuncheng Bei (16546095)
Έκδοση: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
ανά: Yuncheng Bei (16546095)
Έκδοση: (2025)

Table S1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
ανά: Noor Jailkhani (16015810)
Έκδοση: (2025)

Table S2 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
ανά: Noor Jailkhani (16015810)
Έκδοση: (2025)

Table S3 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
ανά: Noor Jailkhani (16015810)
Έκδοση: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
ανά: Steven B. Maron (15044607)
Έκδοση: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Cannot write session to /tmp/vufind_sessions/sess_4o6tf5cnrct65c7qn2sornpg39